Neuphoria Therapeutics Inc. (NEUP) — SEC Filings
Neuphoria Therapeutics Inc. (NEUP) — 41 SEC filings. Latest: 8-K (Dec 18, 2025). Includes 16 8-K, 7 DEFA14A, 4 10-Q.
View Neuphoria Therapeutics Inc. on SEC EDGAR
Overview
Neuphoria Therapeutics Inc. (NEUP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 18, 2025: Neuphoria Therapeutics Inc. filed an 8-K on December 18, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard, and a transfer of listing. The company was formerly known as Bionomics Limited/FI until September 20, 2002.
Sentiment Summary
Across 41 filings, the sentiment breakdown is: 1 bullish, 5 bearish, 32 neutral, 3 mixed. The dominant filing sentiment for Neuphoria Therapeutics Inc. is neutral.
Filing Type Overview
Neuphoria Therapeutics Inc. (NEUP) has filed 16 8-K, 7 DEFA14A, 4 10-Q, 2 DEF 14A, 2 10-K, 1 SC 13G, 4 SC 13G/A, 1 SC 13D/A, 3 6-K, 1 20-F/A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (41)
Risk Profile
Risk Assessment: Of NEUP's 33 recent filings, 6 were flagged as high-risk, 14 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$9.91M |
| EPS | -$4.41 |
| Debt-to-Equity | 1.19 |
| Cash Position | $13.65M |
| Operating Margin | N/A |
| Total Assets | $27.34M |
| Total Debt | $14.83M |
Key Executives
- Alan Fisher
- Peter Miles Davies
- David Wilson
- Dr Spyros Papapetropoulos
- Dr. Steven Michael
- Dr. Paul R. Edick
- Ms. Sarah J. Grow
- Christian Angermayer
- Fabian Hansen
- Julien Höfer
- Spyridon "Spyros" Papapetropoulos, M.D.
Industry Context
Neuphoria Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focused on drug development. This industry is characterized by long development cycles, high R&D costs, significant regulatory hurdles, and the need for substantial funding to advance pipeline candidates through clinical trials and to market. Success often depends on innovation, intellectual property, and the ability to secure partnerships or further investment.
Top Tags
regulatory-filing (8) · proxy-statement (6) · sec-filing (5) · delisting (4) · 10-Q (3) · financials (3) · listing-standards (2) · corporate-governance (2) · Biotechnology (2) · Clinical Trials (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Filing Date | 20251204 | Date Neuphoria Therapeutics Inc. filed these definitive additional materials. |
| Net Loss | $9.91M | Increased from $0.80M in Q3 2024, indicating significant financial deterioration. |
| R&D Expenses | $3.79M | More than doubled from $1.90M in Q3 2024, driving increased operating costs. |
| Loss on Fair Value Adjustments | $4.37M | Shifted from a $2.87M gain in Q3 2024, significantly impacting other income/loss. |
| Cash and Cash Equivalents | $13.65M | Decreased from $14.21M at June 30, 2025, highlighting ongoing cash burn. |
| Accumulated Deficit | $188.3M | Indicates a long history of losses and the need for substantial future profitability. |
| Accompanying Warrants Liability | $8.09M | Increased significantly from $3.70M at June 30, 2025, contributing to total liabilities. |
| Common Shares Outstanding | 2,357,613 | Increased from 1,978,460 at June 30, 2025, indicating recent equity issuance. |
| Net Loss Per Share | $4.41 | Increased from $0.62 in Q3 2024, reflecting higher losses and share count. |
| Annual Meeting Date | 2025-12-09 | Date of Neuphoria Therapeutics Inc.'s virtual Annual Meeting of Stockholders |
| Annual Meeting Time | 10:00 a.m. | Eastern Time for the virtual Annual Meeting |
| Record Date | 2025-10-15 | Date for determining stockholders entitled to vote at the Annual Meeting |
| Shares Outstanding | 2,357,613 | Number of Common Stock shares entitled to vote as of the Record Date |
| Proxy Solicitation Cost | $12,000 | Estimated cost for retaining Morrow Sodali LLC for proxy solicitation |
| Director Term Length | 3 | Years for which Class I directors will serve if re-elected |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Neuphoria Therapeutics Inc. (NEUP)?
Neuphoria Therapeutics Inc. has 41 recent SEC filings from Jan 2024 to Dec 2025, including 16 8-K, 7 DEFA14A, 4 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of NEUP filings?
Across 41 filings, the sentiment breakdown is: 1 bullish, 5 bearish, 32 neutral, 3 mixed. The dominant sentiment is neutral.
Where can I find Neuphoria Therapeutics Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Neuphoria Therapeutics Inc. (NEUP) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Neuphoria Therapeutics Inc.?
Key financial highlights from Neuphoria Therapeutics Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for NEUP?
The investment thesis for NEUP includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Neuphoria Therapeutics Inc.?
Key executives identified across Neuphoria Therapeutics Inc.'s filings include Alan Fisher, Peter Miles Davies, David Wilson, Dr Spyros Papapetropoulos, Dr. Steven Michael and 6 others.
What are the main risk factors for Neuphoria Therapeutics Inc. stock?
Of NEUP's 33 assessed filings, 6 were flagged high-risk, 14 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Neuphoria Therapeutics Inc.?
Forward guidance and predictions for Neuphoria Therapeutics Inc. are extracted from SEC filings as they are enriched.